Overview
Chemring is the world leader in the design, development, and manufacture of advanced expendable countermeasures for protecting air and sea platforms against the growing threat of guided missiles. The Countermeasures and Energetics segment provides high-reliability, single-use devices that perform critical functions for the space, aerospace, defense, and industrial markets including satellite deployment, aircrew egress, and aircraft safety systems.
...
Read More The Sensors and Information segment's products include core technologies for detecting, intercepting, and jamming electronic communications, and world-leading systems for detecting biological agents. Chemring's customer base spans national defense organizations, security and law enforcement agencies, as well as commercial markets such as space, medical, and transport. Most of its revenue comes from the UK.
Read Less
Read More The Sensors and Information segment's products include core technologies for detecting, intercepting, and jamming electronic communications, and world-leading systems for detecting biological agents. Chemring's customer base spans national defense organizations, security and law enforcement agencies, as well as commercial markets such as space, medical, and transport. Most of its revenue comes from the UK.
Read Less
Sarah Louise Ellard
See more contacts
Management of Companies and Enterprises
,
Navigational, Measuring, Electromedical, and Control Instruments Manufacturing
,
Holding companies, nec
,
Measuring and controlling devices, nec
?
$684.37 million
Actual
8%
631.48%
$692
OCT
?
?
London SETS:CHG
Contacts
Get in Touch with 8 Principals* and 167 Contacts
-
Sarah Louise EllardDirector and Company Secretary
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of October 31, 2024 (12 month period) in USD
Annual Revenue 2024
$684.37 million
USD
Actual
1 USD = 0.7458 GBP
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | $109 | $88 | $108 |
| Net Investing Cash | -$64 | -$53 | -$41 |
| Net Financing Cash | -$50 | -$54 | -$48 |
| Net Change in Cash | -$5 | -$18 | $19 |
| Cash at Beginning of Period | $9 | $27 | $7 |
| Cash at End of Period | $3 | $9 | $27 |
| Capital Expenditure | -$93 | -$46 | -$46 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $60 | $9 | $27 |
| Accounts Receivable | $62 | $55 | $45 |
| Inventories | $170 | $136 | $134 |
| Other Current Assets | $69 | $46 | $38 |
| Asset Summary | |||
| Total Current Assets | $362 | $246 | $243 |
| Tangible Fixed Assets | $386 | $325 | $310 |
| Intangible Assets | $38 | $36 | $62 |
| Total Assets | $692 | $596 | $620 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $37 | $22 | $20 |
| Short-Term Debt | $58 | $ | $ |
| Other Current Liabilities | $202 | $169 | $133 |
| Liability Summary | |||
| Total Current Liabilities | $298 | $191 | $152 |
| Long-Term Debt | $59 | $19 | $28 |
| Other Long-Term Liabilities | $ | $ | $ |
| Total Liabilities | $450 | $292 | $271 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $4 | $4 | $4 |
| Retained Earnings | $70 | $84 | $117 |
| Equity Summary | |||
| Total Equity | $478 | $508 | $561 |
| Shares Outstanding | 269,474,911 | 279,480,992 | 283,541,742 |